Terrie Curran

Terrie Curran

DirectoratPhathom Pharmaceuticals· In proxies 2022–2025

Pay in FY2023-32% from the year before · Phathom Pharmaceuticals stock -18.6% the same year

Terrie Curran was paid $3.4M in FY2023 (Dec), down 32%. Phathom Pharmaceuticals stock fell 18.6% that year.

Pay$100 in the stock at the end of FY21 → $46
Pay is from the Summary Compensation Table of each Phathom Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Arcutis BiotherapeuticsPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  2. Phathom PharmaceuticalsPublic company · 4 yr
    • President and Chief Executive Officer2022 – Present · 4 yrStock in role -69%
  3. Myovant Sciences Ltd.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Arcutis BiotherapeuticsDirector · 5 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?